FindTrial
Sign In

Clinical value of serum KL-6 levels and chest HRCT in predicting the risk of mortality in severe COVID-19 patients

Clinical value of serum KL-6 levels and chest HRCT in predicting the risk of mortality in severe COVID-19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070525
Enrollment
Unknown
Registered
2023-04-14
Start date
2023-04-20
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

survival group:none
non-survival group:none

Sponsors

Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Diagnostic criteria: adult patients (>18 years old) with COVID-19 infection and pneumonia. Inclusion criteria: Clinical data, including age, gender, past history, clinical related blood test indicators including KL-6, completion of chest HRCT examination 48 hours before hospitalization or within 24 hours after hospitalization.

Exclusion criteria

Exclusion criteria: Exclusion criteria: COVID-19 infection without pneumonia, previous interstitial lung disease underlying diseases, and incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
28-day mortality;—

Countries

China

Contacts

Public ContactZou Jing

Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

drzouj@163.com+86 13818108334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026